MAKE PROTECTION YOUR SUPERPOWER
Protect your patients who have cardio, renal, and metabolic conditions.
Shorts
Christiane Angermann (Germany) | Ricardo Carvalho (Portugal)
Clinical relationship between the heart and the kidneys
Subodh Verma (Canada)
Why should empagliflozin be your first choice in heart failure management?
Lee-Ling Lim (Malaysia)
Reducing the risk of diabetic ketoacidosis when initiating SGLT2 inhibitors
Upcoming Events
Heart Failure 360: Early protection for every heart failure patient
Past Events
Subodh Verma (Canada) | Soo Yong Lee (Korea)
SGLT2 inhibitor: Essential foundation for heart failure treatment (Summary 2)
Subodh Verma (Canada) | Soo Yong Lee (Korea)
SGLT2 inhibitor: Essential foundation for heart failure treatment (Summary 1)
Subodh Verma (Canada) | Soo Yong Lee (Korea)
